Therapeutic effects of selective p300 histone acetyl-transferase inhibitor on liver fibrosis.

ABSTRACT: Liver fibrosis is caused by chronic liver damage and results in the aberrant accumulation of extracellular matrix during disease progression. Despite the identification of the HAT enzyme p300 as a major factor for liver fibrosis, the development of therapeutic agents targeting the regulation of p300 has not been reported. We validated a novel p300 inhibitor (A6) on the improvement of liver fibrosis using two mouse models, mice on a choline-deficient high-fat diet and thioacetamide-treated mice. We demonstrated that pathological hall-marks of liver fibrosis were significantly diminished by A6 treatment through Masson's trichrome and Sirius red staining on liver tissue and found that A6 treatment reduced the expression of matricellular protein genes. We further showed that A6 treatment impro

SUBMITTER: Kim H 

PROVIDER: S-EPMC9978366 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature